• Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Dividend Stocks Report
No Result
View All Result
Home Stock News

First U.S. omicron patient was fully vaccinated and has mild Covid symptoms, officials say

by
December 1, 2021
in Stock News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Related Posts

Pending home sales post surprise increase in May, likely due to brief pullback in mortgage rates

S&P 500 is little changed as stocks struggle to maintain their comeback from bear market lows

Trump SPAC deal threatened by federal criminal probe

UiPath to cut 5% of its workforce as part of restructuring plan

Gov. Gavin Newsom takes questions during a press conference on COVID-19 vaccination and housing for homeless veterans at the West Los Angeles VA Medical Center in Los Angeles on Wednesday, November 10, 2021.

Sarah Reingewirtz | MediaNews Group | Los Angeles Daily News via Getty Images

The individual in California who tested positive for the omicron variant of the virus that causes Covid-19 was fully vaccinated, but has mild symptoms and is improving, U.S. health officials said on Wednesday.

The patient was otherwise healthy when they returned to the San Francisco Bay from traveling in South Africa on Nov. 22, developed symptoms three days later and tested positive for Covid on Nov. 29, according to public health officials in California.

Scientists at the University of California San Francisco received the patient’s sample around 3 p.m. Pacific time Tuesday and completed the sequencing in about five hours, lab director Dr. Charles Chiu told reporters at a press conference Wednesday with San Francisco Mayor London Breed.

Gov. Gavin Newsom, in a separate briefing Wednesday, said the patient is between 18 and 49 and had not received a booster shot because they were not six months out from their original vaccination course.

“This individual has not been hospitalized,” Newsom said. “The individuals that this individual has come into contact with have not tested positive yet to our knowledge and we are hopeful of full recovery, and expect nothing less based on what we’ve learned.”

The Centers for Disease Control and Prevention has recommend that all U.S. adults get a booster six months after their original Pfizer or Moderna two-dose course, and two months after their single J&J shot.

Dr. Mark Ghaly, California’s Health and Human Services secretary, said the fact that the patient is improving underscores the importance of vaccination.

“We have been talking for months about the fact that vaccinations do one really, really important thing — protect against severe disease, against hospitalization and death,” Ghaly told reporters at the briefing with Newsom. “The evidence that an individual with omicron identified by sequencing actually has mild symptoms, is improving, I think is a testimony to the importance of the vaccinations.”

Ghaly said there’s still a lot to learn about the variant, but encouraged Californians to get vaccinated and get a booster shot if eligible.

White House chief medical advisor Dr. Anthony Fauci told reporters on Wednesday that the profile of the omicron variant suggests its mutations could reduce the effectiveness of the vaccines currently on the market, but more data is needed.

“The molecular profile of the kinds of mutations that you see (in omicron) would suggest that it might be more transmissible and that it might elude some of the protection of vaccines,” Fauci said Wednesday. “But we don’t know that now.”

The CEOs of Moderna and Pfizer have said it will take about two weeks to determine how much omicron impacts the effectiveness of the current vaccines.

“I don’t think that the result will be the vaccines don’t protect,” Pfizer CEO Albert Bourla told CNBC on Monday. “I think the result could be, which we don’t know yet, the vaccines protect less.”

Bourla said Pfizer can develop a new vaccine within 100 days. The company was able to quickly create vaccines for the beta and delta Covid variants, but ended up not using them because the originally vaccine remained effective against the mutations, he said.

Moderna CEO Stephane Bancel said the vaccine maker can roll out a higher dosage booster shot quickly, but it could take until early 2022 to develop and ship a shot that specifically targets omicron.

“The higher dose could be done right away but it will be months before the omicron specific variant is ready to ship in massive quantities,” Bancel told CNBC’s “Squawk Box” on Monday.

Maria Van Kerkhove, the World Health Organization’s Covid technical lead, said on Wednesday said reports from South Africa indicate some patients infected with omicron show mild symptoms, but in other cases the disease has become more severe. Van Kerkhove said studies are looking at those hospitalized to see if they have the omicron variant or not.

“It is certainly possible that one of the scenarios is that the virus, as it continues to evolve, may still have a fitness advantage, meaning that it can become more transmissible than delta, we’ll have to see,” she said. “But we don’t know quite yet about the severity.”

Next Post

November Vehicles Sales decreased to 12.9 million SAAR

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Stock News

UiPath to cut 5% of its workforce as part of restructuring plan

by
June 27, 2022
0

In this article PATH PATH UiPath IPO at the New York Stock Exchange. Source: NYSE UiPath will reduce roughly 5%...

Read more

UiPath to cut 5% of its workforce as part of restructuring plan

Trump SPAC deal threatened by federal criminal probe

S&P 500 is little changed as stocks struggle to maintain their comeback from bear market lows

Pending home sales post surprise increase in May, likely due to brief pullback in mortgage rates

Trump-Tied SPAC Tumbles After Disclosing Grand Jury Subpoena

NAR: Pending Home Sales Increased 0.7% in May

Load More

All rights reserved by www.dividendstocksreport.net

  • Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.